Drug maker Cipla has written to National Pharmaceutical Pricing Authority (NPPA), the drug price r..

Drug maker Cipla has written to National Pharmaceutical Pricing Authority (NPPA), the drug price regulator to allow price hike of certain respiratory medications citing substantial rise in cost of a critical ingredient called propellant P227. According to the letter, titled, Request for an increase in prices of respiratory formulations due to substantial price hike of propellant P227, the production of these medicines is becoming expensive.

Read the source article at mmb.moneycontrol.com
2021-09-07 20:11:00